View Author
patient bortezomib myeloma response trial study therapy neuropathy dexamethasone analysis blood richardson survival treatment phase sample journal grade bene fit signi month research disease impairment signi ficantly response rate ef ficacy table expression british journal cancer dose modi fication result subgroups classi cycle baseline dexamethasone patients millennium pharmaceuticals quality figure erasmus mc bortezomib arm high-dose fication incidence group marrow grade ‡2 genomic thalidomide number england journal cell transplantation progression dose-modi fication guideline transplantation blade cohort bortezomib patients population apex trial speci ficacy outcome haematology gene expression score british ficantly prognostic johnson comparison reduction proteasome hospital fi rst response high-dose dexamethasone impact anderson
6 Most Recent Publications
|
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma
(Article)
Vogl, D.T. Stadtmauer, E.A. Anderson, K.C. Richardson, P.G. Sonneveld, P. Schuster, M.W. Irwin, D. Facon, T. Harousseau, J-L. Boral, A.L. Neuwirth, R. |
2009-11-01
|
|
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline
(Article)
Richardson, P.G. Sonneveld, P. Bladé, J. Boccadoro, M. Cavenagh, J. Boral, A.L. Esseltine, D-L. Wen, P.Y. Amato, A.A. Anderson, K.C. San Miguel, J-F. Schuster, M.W. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. Goldschmidt, H. Reece, D. |
2009-03-01
|
|
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma
(Article)
Niesvizky, R. Richardson, P.G. Harousseau, J-L. Boral, A.L. Esseltine, D-L. Anderson, K.C. Bladé, J. Rajkumar, S.V. Coleman, M. Rosiñol, L. Sonneveld, P. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T. |
2008-10-01
|
|
Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study
(Article)
San Miguel, J-F. Richardson, P.G. Goldschmidt, H. Reece, D. Bladé, J. Boccadoro, M. Cavenagh, J. Neuwirth, R. Boral, A.L. Esseltine, D-L. Anderson, K.C. Sonneveld, P. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. |
2008-04-01
|
|
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial
(Article)
Richardson, P.G. Sonneveld, P. Reece, D. San Miguel, J-F. Bladé, J. Boccadoro, M. Cavenagh, J. Alsina, M. Rajkumar, S.V. Lacy, M. Jakubowiak, A.J. Dalton, W. Schuster, M.W. Boral, A.L. Esseltine, D-L. Schenkein, D. Anderson, K.C. Irwin, D. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. Goldschmidt, H. |
2007-11-15
|
|
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
(Article)
Mulligan, G. Mitsiades, C. Trepicchio, W.L. Broyl, A. Sonneveld, P. Shaughnessy, J. Bergsagel, P.L. Schenkein, D. Esseltine, D-L. Boral, A.L. Anderson, K.C. Bryant, B. Zhan, F. Chng, W.J. Roels, S. Koenig, E. Fergus, A. Huang, Y. Richardson, P.G. |
2007-04-15
|
